Biofrontera Inc has a consensus price target of $11.33 based on the ratings of 3 analysts. The high is $20 issued by Roth Capital on November 24, 2021. The low is $7 issued by Benchmark on August 16, 2024. The 3 most-recent analyst ratings were released by Benchmark on August 16, 2024, August 31, 2023, and July 5, 2023, respectively. With an average price target of $14.33 between Benchmark, there's an implied 1002.56% upside for Biofrontera Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Biofrontera (NASDAQ:BFRI) was reported by Benchmark on August 16, 2024. The analyst firm set a price target for $7.00 expecting BFRI to rise to within 12 months (a possible 438.46% upside). 1 analyst firms have reported ratings in the last year.
The latest analyst rating for Biofrontera (NASDAQ:BFRI) was provided by Benchmark, and Biofrontera reiterated their buy rating.
There is no last upgrade for Biofrontera
There is no last downgrade for Biofrontera.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biofrontera, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biofrontera was filed on August 16, 2024 so you should expect the next rating to be made available sometime around August 16, 2025.
While ratings are subjective and will change, the latest Biofrontera (BFRI) rating was a reiterated with a price target of $7.00 to $7.00. The current price Biofrontera (BFRI) is trading at is $1.30, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.